Men’s Decision-Making About Predictive BRCA1/2 Testing: The Role of Family
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Men who have a family history of breast and/or ovarian cancer may be offered a predictive genetic test to determine whether or not they carry the family specific BRCA1/2 mutation. Male carriers may be at increased risk of breast and prostate cancers. Relatively little is known about at-risk men’s decision-making about BRCA1/2 testing. This qualitative study explores the influences on male patients’ genetic test decisions. Twenty-nine in-depth interviews were undertaken with both carrier and noncarrier men and immediate family members (17 male patients, 8 female partners, and 4 adult children). These explored family members’ experiences of cancer and genetic testing, decision-making about testing, family support, communication of test results within the family, risk perception and risk management. Implicit influences on men’s testing decisions such as familial obligations are examined. The extent to which other family members—partners and adult children—were involved in testing decisions is also described. It is demonstrated that mothers of potential mutation carriers not only perceive themselves as having a right to be involved in making this decision, but also were perceived by their male partners as having a legitimate role to play in decision-making. There was evidence that (adult) children were excluded from the decision-making, and some expressed resentment about this. The implications of these findings for the practice of genetic counseling are discussed.
- Armstrong, K., Calzone, K., Stopfer, J., Fitzgerald, G., Coyne, J., & Weber, B. (2000). Factors associated with clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev, 9, 1251–1254.
- Beauchamp, T. L., & Childress, J. F. (1994). Principles of Biomedical Ethics, 4th ed. New York: Oxford University Press.
- Bodd, T. L., Reichelt, J., Heimdal, K., & Moller, P. (2003). Uptake of BRCA1 testing in adult sisters and daughters of known mutation carriers in Norway. J Genet Couns, 12, 405–417. CrossRef
- Brandt, R., Hartmann, E., Ali, Z., Tucci, R., & Gilman, P. (2002). Motivations and concerns of women considering genetic testing for breast cancer: A comparison between affected and at-risk probands. Genet Testing, 6, 203–205. CrossRef
- Claes, E., Evers-Kiebooms, G., Boogaerts, A., Decruyenaere, M., Denayer, L., & Legius, E. (2003). Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet, 116A, 11–19. CrossRef
- Culler, D. D., Silberg, J., Vanner-Nicely, L., Ware, J. L., Jackson-Cook, C., & Bodurtha, J. (2002). Factors influencing men’s interest in gene testing for prostate cancer susceptibility. J Genet Couns, 11, 383–398. CrossRef
- D’Agincourt-Canning, L. (2001). Experiences of genetic risk: Disclosure and the gendering of responsibility. Bioethics, 15, 231. CrossRef
- Daly, P. A., Nolan, C., Green, A., Ormiston, W., Cody, N., McDevitt, T., et al. (2003). Predictive testing for BRCA1 and 2 mutations: A male contribution. Ann Oncol, 14, 549–553. CrossRef
- Easton, D., Steele, L., Fields, P., et al. (1997). Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13 q12-13. Am J Hum Genet, 61, 120–128.
- Easton, D. F., Ford, D., Bishop, D. T., & The Breast Cancer Linkage Consortium. (1995). Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet, 56, 265–271.
- Fanos, J. H., & Johnson, J. P. (1995). Barriers to carrier testing for adult cystic fibrosis sibs: The importance of not knowing. Am J Med Genet, 59, 85–91.
- Ford, D., Easton, D. F., & Peto, J. (1995). Estimates of gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence Am J Hum Genet, 57, 1457–1462.
- Foster, C., Evans, D. G. R., Eeles, R., Eccles, D., Ashley, S., Brooks, L., et al. (2002). Predictive testing for BRCA1/2: Attributes, risk perception and management in a multi-centre clinical cohort. Br J Cancer, 86, 1209–1216. CrossRef
- Goelen, G., Rigo, A., Bonduelle, M., & De Greve, J. (1999). Moral concerns of different types of patients in clinical BRCA1/2 gene mutation testing. J Clin Oncol, 17, 1595.
- Haites, N. (2003). The ethical management of genetic testing. Eur J Cancer, 39, 1339–1340. CrossRef
- Hallowell, N. (1998). “You don’t want to lose your ovaries because you think ‘I might become a man’.”: Women’s perceptions of prophylactic surgery as a cancer risk management option. Psychooncology, 7, 263–275. CrossRef
- Hallowell, N. (1999). Doing the right thing: Genetic risk and responsibility. Sociol Health Illn, 21, 597–621. CrossRef
- Hallowell, N., Foster, C., Eeles, R., Ardern-Jones, A., Murday, V., & Watson, M. (2002). Genetic testing for women previously diagnosed with breast/ovarian cancer: Examining the impact of BRCA1 and BRCA2 mutation searching. Genet Testing, 6, 79–87. CrossRef
- Hallowell, N., Foster, C., Eeles, R., Ardern-Jones, A., Murday, V., & Watson, M. (2003). Balancing autonomy and responsibility: The ethics of generating and disclosing genetic information. J Med Ethics, 29, 74–79. CrossRef
- Juengst, E. T. (1999). Genetic testing and the moral dynamics of family life. Public Understand Sci, 8, 193–205. CrossRef
- Julian-Reynier, C., Sobol, H., Sevilla, C., Nogues, C., Bourret, P., & French Cancer Genetic Network. (2000). Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network. Psychooncology, 9, 504–510.
- Liede, A., Metcalfe, K., Hanna, D., Hoodfar, E., Snyder, C., Durham, C., et al. (2000). Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet, 67, 1494–1504. CrossRef
- Lodder, L., Frets, P. G., Trijsburg, R. W., Tibben, A., Meijers-Heijboer, E. J., Duivenvoorden, H. J., et al. (2001). Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: An exploration of attitudes and psychological functioning during genetic testing. Eur J Hum Genet, 9, 492–500. CrossRef
- McAllister, M. (2004). On being used by research participants. In N. Hallowell, J. Lawton, & S. Gregory (Eds.), Reflections on Research: The Realities of Doing Research in the Social Sciences. Maidenhead, UK: Open University Press.
- McAllister, M. F., Evans, D. G., Ormiston, W., & Daly, P. (1998). Men in breast cancer families: A preliminary qualitative study of awareness and experience. J Med Genet, 35, 739–744.
- Nuffield Council of Bioethics. (1993). Genetic Screening: Ethical Issues. London: Nuffield Trust.
- O’Neill, O. (2002). Autonomy and Trust in Bioethics. Cambridge, UK: Cambridge University Press.
- Petersen, A., & Bunton, R. (2002). The New Genetics and the Public’s Health. London: Routledge.
- Strauss, A., & Corbin, J. (1990). Basics of Qualitative Research. London: Sage.
- The Breast Cancer Linkage Consortium. (1999). Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst, 91, 1310–6.
- Van Riper, M., & McKinnon, W. C. (2004). Genetic testing for breast and ovarian cancer susceptibility: A family experience. J Midwifery Womens Health, 49, 210–219. CrossRef
- Wexler, N. (1995). Mapping Fate: A Memoir of Family, Risk and Genetic Research. New York: Random House.
- Whittemore, A. S., Gong, G., & Itnyre, J. (1998). Prevalence and contribution of BRCA1 mutations in breast and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet, 60, 496–504.
- Men’s Decision-Making About Predictive BRCA1/2 Testing: The Role of Family
Journal of Genetic Counseling
Volume 14, Issue 3 , pp 207-217
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- BRCA1/2 testing
- Industry Sectors
- Author Affiliations
- 1. Public Health Sciences, The Medical School, University of Edinburgh, United Kingdom
- 7. Public Health Sciences, The Medical School, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, United Kingdom
- 2. Cancer Genetics Clinic, The Royal Marsden NHS Foundation Trust, London, United Kingdom
- 3. Translational Cancer Genetics Team and Cancer Genetics Unit, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
- 4. Macmillan Research Unit, School of Nursing and Midwifery, University of Southampton, United Kingdom
- 5. Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, United Kingdom
- 6. Department of Psychological Medicine, Royal Marsden Hospital, London, United Kingdom